---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-045266"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T00:55:22.697535+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verastem outlines NDA filing plan for avutometinib/defactinib in LGSOC by H1 2024; cash $137.1M

## Summary
- Topline data from RAMP 201 trial of avutometinib + defactinib in LGSOC expected H1 2024; rolling NDA for accelerated approval to commence same period.
- Confirmed ORR of 45% with tumor shrinkage in 86% of evaluable patients from RAMP 201 Part A (June 2023 data).
- GenFleet partnership: IND for oral KRAS G12D inhibitor GFH375/VS-7375 expected in China H1 2024; Phase 1 initiation H2 2024.
- Initial safety/efficacy data from RAMP 205 (avutometinib + gemcitabine/nab-paclitaxel + defactinib) in front-line metastatic pancreatic cancer due H1 2024.
- Ended Q4 2023 with $137.1M cash; GAAP operating expenses $31.14M ($29.54M non-GAAP) in Q4 2023.

## SEC filing metadata
- accession: 0001104659-24-045266
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465924045266/0001104659-24-045266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465924045266/tm2411327d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-045266
- JSON: https://secwatch.observer/filing/0001104659-24-045266.json
- Plain text: https://secwatch.observer/filing/0001104659-24-045266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.